OmicsCare was founded in 2026 by Dr. Mohammad Sina, a scientist whose research bridges hereditary cancer genetics, pediatric immunogenetics, and clinical genomics. Dr. Sina's work - conducted in collaboration with researchers at the University of Brescia and international experts leading authorities on hereditary cancer syndromes - has contributed to the identification and clinical management of Lynch syndrome and other inherited cancer predispositions across the Middle East, North Africa, and Europe.
His peer-reviewed research spans antibody engineering, Mendelian disorder diagnostics, and germline variant interpretation, published in journals including Familial Cancer, the European Journal of Cancer Prevention, and Cancer Genetics. Building on this scientific foundation, Dr. Sina founded OmicsCare to translate advanced genomic research into accessible, AI-powered tools for clinicians and patients worldwide.
"Our mission is to bridge the gap between discovery and diagnosis - making precision medicine accessible, ethical, and effective for all."
- Dr. Mohammad Sina, Founder
